Latest Breaking News On - Global medical head - Page 1 : comparemela.com

Johnson & Johnson : Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

News Release Media Contact: Christie Corbett +1 857-636-0211 Satu Glawe +49 172-294-6264 Investor Relations: Raychel. | June 5, 2023

United statesArnob banerjeeSatu glaweChristie corbettYael cohenEuropean commissionNational comprehensive cancer networkEarly development oncologyAmerican society of clinical oncologyJanssen pharmaceutical companies of johnsonJanssen research developmentAviv sourasky medical centerHematology instituteNews releasePresents first ever resultsDual bispecific combination

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first-ever results from the Phase 1b RedirecTT-1 study of.

United statesChristie corbettArnob banerjeeYael cohenSatu glaweEarly development oncologyCompanies of johnsonJanssen pharmaceutical companies of johnsonNational comprehensive cancer networkNone of the janssen pharmaceutical companiesAmerican society of clinical oncologyJanssen biotech incNational cancer instituteAmerican cancer societyJanssen research developmentExchange commission

Janssen Presents First Results from Dual Bispecific

BEERSE, BELGIUM, June 03, 2023 (GLOBE NEWSWIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the first results from.

United statesRegion flamandeEdmond chanYael cohenArnob banerjeeCompanies of johnsonCommittee for medicinal products human useJanssen research developmentHematology institute telEarly development oncologyAviv sourasky medical centerAmerican society of clinical oncologyJanssen pharmaceutical companies of johnsonEuropean medicines agencyAmerican cancer societyNone of the janssen pharmaceutical companies

Janssen Presents Longer-Term Talquetamab Follow-Up Data

Additional long-term data from the TRiMM-2 study in patients receiving talquetamab and DARZALEX® (daratumumab) subcutaneous (SC) formulation combination.

United statesCastillay leópRegion flamandeTalquetamab monotherapyMaria victoria mateosEdmond chanChris heuckJanssen pharmaceutical companies of johnsonNone of the janssen pharmaceutical companiesAmerican society of clinical oncologyEuropean commission grants marketing authorisationCompanies of johnsonAmerican cancer societyEuropean medicines agencyExchange commissionUniversity hospital of salamanca

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma

Janssen Presents First-Ever Results from Dual Bispecific Combination Study Showing 96 Percent Overall Response Rate in Patients with Relapsed or Refractory Multiple Myeloma
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSatu glaweChristie corbettYael cohenArnob banerjeeEarly development oncologyNational cancer instituteExchange commissionDrug administrationAmerican society of clinical oncologyNational comprehensive cancer networkJanssen pharmaceutical companiesJanssen pharmaceutical companies of johnsonNone of the janssen pharmaceutical companiesCompanies of johnsonJanssen research development